



Complex Effectiveness of General Immunity in Modulating the Specific Immune Response in Gliomas

Lawrence M Agius*

Department of Pathology, Mater Dei Hospital, University of Malta Medical School, Malta

Abstract

Construed determinants within immune reactivity frameworks allow a permissive microenvironment of high grade gliomas to participate within systems of modulated response in terms of targeting events. The significance for reproduction of glioma attributes is system specification as determined by dynamics of a generalized systemic response of such modulated immunity. The participation of injury to the individual glioma cell is further projected within frameworks of such reappraisal as evidenced by emergence of the glioma lesion per se, and as further targeting of an immune response specified by dynamics of proliferation and spread of high grade glioma cells intracranially.

Introduction

The conceptual framework for the development of immune response to intracranial gliomas constitutes a realization that potential attack involvement is a prerogative of immune reactivity in general terms. The ultimate success of immunotherapy in the Central Nervous System (CNS) depends on improved imaging technologies and analysis of the tumor microenvironment [1]. Evidence suggests that vaccine strategies, such as the dendritic cell, heat shock protein or EGFRvIII vaccines may provide promise for promoting immunogenicity [2]. It is also reasonable to consider the derivative dimensions of antigen presentation as an attribute that determines a whole spectrum of reactivity's within the further development of autoimmunity on the one hand and the traditional concepts of immune privilege of the central nervous system. Emerging themes indicate the importance of mitigating the immunosuppressive tumor microenvironment and the potential for innate immune cell activation to enhance cytotoxic anti-tumor activity [3]. It is indeed relevant to consider derivative dimensions of immune reactivity as a plural phenomenon as dictated by heterogeneity of high grade gliomas in general. Major types of immunotherapy include vaccines, cell-based therapies, and immune checkpoint modulators for glioblastoma [4].

OPEN ACCESS

*Correspondence:

Lawrence M Agius, Department of Pathology, Mater Dei Hospital, Tal-Qroqq, University of Malta Medical School, Msida, Malta, Tel: 356-21451752;

E-mail: lawrence.agius@um.edu.mt

Received Date: 25 May 2020

Accepted Date: 29 Jul 2020

Published Date: 03 Aug 2020

Citation:

Agius LM. Complex Effectiveness of General Immunity in Modulating the Specific Immune Response in Gliomas. *Ann Integr Oncol.* 2020; 1(1): 1004.

Copyright © 2020 Lawrence M Agius. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Antigen Presentation

The distributive biology of antigen presentation within the CNS confirms the further potentiality for development of concepts of biology of the immune response, as borne out by systems of enhanced reproducibility of specific dimensions in the immune response as evidenced by glioma biology. Tumors require a re-analysis of currently accepted treatment strategies as well as newly designed approaches [5]. The conclusive dimensions of operability are clearly the immune suppressive attributes of the CNS as partial immune privilege of the CNS. Multiple immunosuppressive mechanisms and micro-invasion result in a complex interplay glioblastoma shares with the immune system [6]. In such terms, the strict experimental confirmation of immune responsiveness to glioma cell proliferation and spread is further defined by systems of response especially of T helper cells on the one hand and of cytotoxic T cells on the other.

Immune System Specificity

Autologous stimulated lymphocytes, cytokines and dendritic cells, immune checkpoint inhibitors, virotherapy and tumor or peptide based vaccines are promising therapies [7]. Genetics and epigenetics of glioblastoma have revealed aberrations in cellular signaling pathways, the tumor microenvironment and pathologic angiogenesis [8].

The potential specificity of the immune response to high grade gliomas is thus a re-evaluation of indices for Major Histocompatibility Complex performance as determined specifically by antigen-presenting cells including microglia and endothelial cells in particular. The future of therapy for glioblastoma will probably involve a combinatorial personalized approach utilizing conventional treatments, active immunotherapeutics, and agents targeting immunosuppressive check points [9].

The distributive dynamics of response as dictated by lymphocytes, macrophages and antigen-presenting cells allow for transformation of an essential permissive micro-environment within systems of ongoing response to foreign antigens. The further cooperative functionality of the intracranial immune response bespeaks for the unfolding redistribution of lymphocytes found in regions of perivascular spaces, cerebrospinal fluid, and also ependyma and choroid plexus. In such dimensions, reproducibility and recurrence of a robust immune response clearly indicate enhancement potentiality as borne out by systems of reproducibility of immunity as further portrayed by reactivated memory immune cell components.

Potential Dynamics

Inclusive dimensions for potential dynamics are substantive component derivation is simple reconstitution of an immune response that further redefines the nature of the intracranial immune response. Checkpoint blockade induces anti-tumor activity by preventing negative regulation of T-cell activation; checkpoint block is probably most effective in combination with a dendritic vaccine or adoptively transferred tumor-specific T cells generated *ex vivo* [10]. The conclusive recovery of such immune response is phylogenetically a derivative natural attribute of the immune system both systemically and intracranially. In such terms, the development of injury and degeneration of actively proliferating and spread of high grade glioma cells is system determined agonistic action within redefined homeostasis and dyshomeostasis of the immune reactivity.

Series of Reactivity's

It is further to such considerations that a full repertoire of reactivity's on the part of the immune system redefines the nature of immunity in general terms. It is significant to consider the further confirmatory evidence as projected by systems of modulation of biologic attributes of the cytotoxic CD8+ lymphocyte subsets. Immunotherapeutic classes under investigation include vaccination strategies, adoptive T cell immunotherapy, immune checkpoint blockade, monoclonal antibodies and cytokine therapies [11].

Receptivity expression on lymphocytes on the one hand and on glioma cells attests for the potential reproduction of immune responses within frameworks of attributes within systems of ongoing transformation. Micro RNAs have been implicated in glioma initiation and progression and miR-1254 inhibits progression *in vivo* and *vitro* of glioma by targeting Colony Stimulating Factor-1 [12]. The persistence of redistribution of lymphocytes within the CNS further attests to an evolutionary series of courses that biologically implicate the immune response. The considerable dimensions for change are dictated strictly by both general immune responsiveness and of also specific immune reactivity to antigens on the surface of glioma cells and of internal determinants within the tumor cells. Optimal implementation in immunotherapy of glioblastoma may depend on familiarity with tumor specific antigens presented as HLA peptides by the glioblastoma cells [13]. By such conceptual determination of the reactive immune response, the overall generalized immunity is specific expression in terms of reactive attack to the dynamics of tumor cell proliferation and spread intracranially.

Immune Response Increments

Powerful increments in the immune response implicate complement production and action within the milieu of adjuvant co-stimulation of the antigenicity of the individual glioma cell. In

such terms, the distributive dynamics of the endothelial cells further attest to potentially strong reactivity's of prioritization of the general immune response as dictated in terms beyond simple frameworks of the specific immune reactivity's. Escape from immunosurveillance is increasingly recognized as a landmark event in cancer biology; glioblastoma has emerged as a model of resistance to immunotherapy [14]. It is beyond such terms that derivational predominance of the general immunity systems of reappraisal implicates a second wave of specific immunity states that determines survival and death of the individual glioma cell in particular.

Significant reappraisal for transformed dynamics of immune response indicate a system modulation as potential dimension for the induction of specific targeting as borne out by modulation on the part by a general immunity response to such antigens as epidermal growth factor variant III. It is to be further realized that the overall conformational antigenicity of the high grade glioma cells is system modulation of the general immune responsiveness in the overall dynamics of reproducibility of specific attack on the individual glioma cell. Immunotherapy *via* adoptive cell transfer especially offers T cells engineered to express chimeric antigen receptors; primary immunologic challenges in glioblastoma implicate antigenic heterogeneity, immune suppression and T-cell exhaustion [15].

Biology of Immunity

Biology of immune responsiveness is a question of attribute specification within the ongoing immune reactivity patterns that modulate and further shape antigenicity as presented by glioma cells to generalized immune system function and dysfunction. In such terms, the systemic dysfunctions of the immune response preselects targeted rejection of the glioma cells as determined in particular by both microglia and dendritic cells found within the neural parenchyma. It is significant to reconsider complement and co-stimulatory molecules as derived redistribution of a series of pathways for further modulation of the immune responsiveness. Research addressing synergism between treatment options is gaining attention [16]. Antigen presentation is a biologic framework for both generalized and specific immune targeting of the individual glioma cell that is actively undergoing both proliferation and spread intracranially. Neoadjuvant anti-programmed cell death protein 1 immunotherapy enhances survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma [17]. The redistributive dimensions of glioma biology are significant reappraisal for further conformation restructuring of the immune response itself. It is within such framework that the characterization of glioma antigenicity conforms to the emergence of the glioma cell as experienced by proliferation and spread of such individual glioma cell.

Concluding Remarks

Complex formulation of incremental nature is a strict requisite to the ongoing potential targeting of the glioma cells as derived immune responsiveness to specific determinants created by active proliferation and spread of the individual glioma cell. Such redistribution of antigenicity is determinant functionality as projected by a general or systemic immune responsiveness that derives and further develops a secondary specificity of the immune response that is carried forward by systems of modulation of the cytotoxic CD8+ lymphocyte subset. Performance indices of such reappraisal are dysfunctional and specific cooperative target creation within the pathway evolution to the

immunity phenomena of the glioma cells that undergo proliferation and spread intracranially.

References

1. Sampson JH, Maus MV, June CH. "Immunotherapy for brain tumors". *J Clin Oncol*. 2017;35(21):2450-6.
2. Schernberg A, Marabelle A, Massard C, Armand JP, Dumont S, Deutsch E, et al. "What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?" *Bull Cancer*. 2016;103(5):484-98.
3. Lieberman NAP, Moyes KW, Crane CA. "Developing immunotherapeutic strategies to target brain tumors." *Expert Rev Anticancer Ther*. 2016;16(7):775-88.
4. Reardon DA, Wen PY, Wucherpennig KW, Sampson JH. "Immunomodulation for glioblastoma". *Curr Opin Neurol*. 2017;30(3):361-9.
5. Wainwright DA, Nigam P, Thaci B, Dey M, Lesniak M. "Recent developments on immunotherapy for brain cancer". *Expert Opin Emerg Drugs*. 2012;17(2):181-202.
6. Cohen-Inbar O, Zaaroor M. "Immunological aspects of malignant gliomas". *Can J Neural Sci*. 2016;43(4):494-502.
7. Weathers SP, Gilbert MR. "Current challenges in designing GBM trials for immunotherapy." *J Neurooncol*. 2016;123(3):331-7.
8. Polka J Jr, Polka J, Holubec L, Kubikova T, Priban V, Hes O, et al. "Advances in experimental targeted therapy and immunotherapy for patients with glioblastoma multiforme." *Anticancer Res*. 2017;37(1):21-33.
9. Huang B, Zhang H, Gu L, Ye B, Zhihong J, Stary C, et al. "Advances in immunotherapy for glioblastoma multiforme." *J Immunol Res*. 2017;2017:3697613.
10. Desai R, Suryadevara CM, Batich KA, Farber SH, Sanchez-Perez L, Sampson JH. "Emerging immunotherapies for glioblastoma." *Expert Opin Emerg Drugs*. 2016;21(2):133-45.
11. Harrison Farber S, Elsamadicy AA, Atik AF, Suryadevara CM, Chongsathidkiet P, Facci PE, et al. "The safety of available immunotherapy for the treatment of glioblastoma." *Expert Opin Drug Saf*. 2017;16(3):277-87.
12. Li X, Kong S, Cao Y. "miR-1254 inhibits progression of glioma *in vivo* and *in vitro* by targeting CSF-1." *J Cell Mol Med*. 2020;24(5):3128-38.
13. Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodan G, Rosner I, et al. "Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma." *Mol Cell Proteomics*. 2019;18(6):1255-68.
14. Jackson CM, Choi J, Lim M. "Mechanisms of immunotherapy resistance: Lessons from glioblastoma." *Nat Immunol*. 2019;20(9):1100-9.
15. Choi BD, Maus MV, June CH, Sampson JH. "Immunotherapy for glioblastoma: Adoptive T-cell strategies." *Clin Cancer Res*. 2019;25(7):2042-8.
16. Miyauchi JT, Tsirka SE. "Advances in immunotherapeutic research for glioma therapy." *J Neural*. 2018;265(4):741-56.
17. Cloughesy TF, Mochizuki A, Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. "Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma." *Nat Med*. 2019;25(3):477-586.